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Background  :  Second-line  chemotherapy  offers  advanced  non-small  cell  lung  cancer  (NSCLC)  patients  a  small,  but 
significant  increase  in  survival.  Docetaxel  is  usually  administered  as  a  3-week  schedule,  yet  there  is  significant  toxicity 
with  this  therapy.  Therefore,  a  weekly  schedule  has  been  explored  in  several  previous  trials.  In  this  retrospective  study, 
we  compared  the  efficacy  and  safety  of  a  weekly  schedule  and  a  3-week  schedule  of  docetaxel  monotherapy  in  a 
second-line  setting.
Methods  :  Docetaxel  was  administered  as  75  mg/m
2  on  day  1  every  3  weeks  or  as  37.5  mg/m
2  on  day  1  and  8 
every  3  weeks  until  disease  progression  or  severe  toxicity  developed.
Results  :  From  October  2003  to  March  2006,  a  total  of  37  patients  received  docetaxel  monotherapy  and  36  patients 
could  be  evaluated.  A  total  of  135  cycles  were  administered  and  then  evaluated.  The  median  overall  survival  was  13.3 
months  (95%  confidence  interval:  6.3～20.3)  for  the  weekly  schedule  and  10.7  months  (95%  confidence  interval:  8.3～
13.0)  for  the  3-week  schedule  (p=0.41).  The  median  time  to  progression  was  3.0  months  (95%  confidence  interval:  1.
9～4.0)  and  2.8  months  (95%  confidence  interval:  1.0～4.6),  respectively  (p=0.41).  The  response  rate  was  16.7%  for  the 
weekly  schedule  and  21.1%  for  the  3-week  schedule.  The  major  form  of  hematologic  toxicity  was  grade  3-4 
neutropenia  (3-week:  38.9%,  weekly:  9.5%).  The  non-hematologic  toxicities  were  similar  between  the  two  schedules. 
There  were  no  treatment-related  deaths.
Conclusions  :  A  docetaxel  weekly  schedule  was  very  tolerable  and  it  had  comparable  activity  to  that  of  the  3-week 
docetaxel  schedule.  Considering  the  efficacy  and  tolerability,  a  docetaxel  weekly  schedule  can  be  an  alternative 
schedule  for  the  standard  treatment  of  NSCLC  in  a  second-line  setting. 
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INTRODUCTION
A  meta-analysis  of  the  published  data  has  shown  a  modest, 
but  significant  survival  benefit  for  platinum-based  chemotherapy 
and  supportive  care  as  compared  to  best  supportive  care  alone 
for  patients  suffering  with  non-small  cell  lung  cancer  (NSCLC)
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Platinum-based  chemotherapy  has  been  regarded  as  a 
standard  treatment  for  patients  with  advanced  NSCLC. 
However,  the  importance  of  second-line  treatment  has  been 
highlighted  in  research  because  most  NSCLC  patients  fail  to 
respond  to  a  front-line  regimen.  Several  reports  have  suggested 
that  docetaxel
2, 3)  or  pemetrexed
4)  are  optimal  regimens  as 
second-line  treatment.
The  administration  of  docetaxel  (Taxotere
Ⓡ;  Aventis 
Pharmaceuticals  Inc.;  Bridgewater,  NJ),  every  3  weeks  at  doses 
of  75～100  mg/m
2  in  phase  II  trials
5, 6)  has  resulted  in  a 
response  rate  of  16%～22%  and  a  survival  period  of  6.9～9.7 
months.  Two  phase  III  trials  (the  TAX317
2)  and  TAX  320
3)) 
displayed  the  superiority  of  docetaxel  at  75  mg/m
2  for 
disease/symptom  control,  survival  and  the  quality  of  life,  and  this 
was  despite  the  relatively  low  response  rate  of  5.5～6.7%  when 
compared  to  the  best  supportive  care  or  an  alternative 
single-agent  such  as  vinorelbine  or  ifosfamide.  In  spite  of  these 
promising  results,  there  were  severe  docetaxel-induced 
toxicities.  Grade  3-4,  severe  neutropenia  occurred  in  85.7%  of 
the  patients  in  the  100  mg/m
2  arm  and  in  67.3%  of  the  patients 
in  the  75  mg/m
2  arm  of  the  TAX  317  trial
2).  In  the  TAX  320  trial
3), 
the  frequency  of  neutropenia  was  significantly  greater  in  the 
docetaxel  group  (54%)  as  compared  to  the  vinorelbine/ 
ifosfamide  group  (31%).  Considering  the  recent  steep  increases 
in  the  incidence  of  elderly  patients  or  patients  with  a  poor 
performance  status  (PS)  who  fail  with  first-line  chemotherapy
7), 
it  seems  that  a  3-week  schedule  of  docetaxel  would  be  difficult 
to  applied  to  these  specific  populations  in  a  clinical  setting.
A  weekly  schedule  may  enable  the  delivery  of  repeated 
effective  doses  with  minimal  toxicity,  which  would  lead  to 
achieving  increased  drug  dose  intensity  and  maximized  efficacy. 
Weekly  schedules  with  the  newer  chemotherapeutic  agents, 
such  as  paclitaxel
8, 9)  and  docetaxel
10-13),  have  recently  been 
intensively  tried  in  advanced  NSCLC  patients.  The  phase  II  and 
III  trials  that  have  compared  a  weekly  schedule  with  a  3-week 
schedule  have  demonstrated  that  a  weekly  schedule  could 
significantly  reduce  grade  3-4  neutropenia  by  2～20%  with 
similar  therapeutic  efficacy
10-13).
We  retrospectively  compared  the  efficacy  and  toxicity  of 
weekly  docetaxel  to  those  of  a  standard  3-week  regimen  as 
second-line  chemotherapy  for  patients  suffering  with  advanced 
NSCLC. 
MATERIALS AND METHODS
Patient's  eligibility
The  eligible  patients  for  this  study  were  treated  from  October 
2003  to  March  2006  at  Kangnam  St.  Mary's  Hospital,  and  they 
were  required  to  have  histological  or  cytological  proof  of  having 
stage  IIIB  or  IV  NSCLC,  and  they  had  least  one  bi- 
dimensionally  measurable  lesion  outside  the  previously  irradiated 
area  and  they  had  received  only  one  prior  platinum-containing 
chemotherapy  regimen.  The  patients  were  also  required  to  have 
a  minimum  ECOG  performance  status  of  (PS)  ≤2  and 
adequate  physiological  organ  functions:  1)  hepatic  function  (a 
normal  bilirubin  level,  a  normal  asparate  aminotransferase  level 
and  a  normal  alanine  aminotransferase  level  ≤1.5  the  upper 
limit  of  normal  (ULN)  and  an  alkaline  phosphatase  level  ≤5 
ULN),  2)  renal  function  (a  serum  creatinine  level  ≤1.5  ULN)  and 
3)  hematological  function  (an  absolute  neutrophil  count  ≥
2×10
9/L,  a  platelet  count  ≥100×10
9/L  and  a  hemoglobin  level  10 
g/dL).
Treatment  schedule
Docetaxel  was  administered  on  a  3-week  or  weekly 
schedule.  Three-week  schedules  were  conducted  from  October 
2003  to  September  2004  and  then  weekly  schedules  were 
conducted  from  October  2004  to  March  2006.  For  the  3-week 
docetaxel  administration  regimen,  docetaxel  75  mg/m
2  was 
given  intravenously  on  day  1  of  a  21-day  cycle,  whereas  during 
the  weekly  regimen,  docetaxel  37.5  mg/m
2  was  administered 
intravenously  on  days  1  and  8  of  a  21-day  cycle.  Docetaxel 
was  administered  intravenously  as  a  1-h  infusion,  whereas 
premedications  (dexamethasone  8  mg  twice  daily  (orally)  the 
day  before  chemotherapy  and  immediately  after  docetaxel 
infusion,  and  ranitidine  50  mg,  diphenhydramine  50  mg  and 
5-hydroxytryptamine  3  receptor  antagonist)  were  administered  at 
the  same  dosage  for  each  schedule.  Docetaxel  was 
discontinued  if  a  patient  experienced  disease  progression, 
irreversible  grade  3/4  toxicity  or  wanted  to  discontinue  the 
treatment.  Chemotherapy  was  postponed  until  attaining  recovery 
of  the  bone  marrow  function.  The  investigators  determined  to 
continue  the  consecutive  chemotherapy  when  the  patients 
experienced  an  objective  decline  in  their  performance  status. 
Efficacy  and  toxicity
The  patients  were  evaluated  using  computed  tomography  for 
determining  the  anti-tumor  efficacy  according  to  the  WHO 
criteria  at  every  2  cycles.  A  complete  response  (CR)  was 
defined  as  the  disappearance  of  all  tumor  lesions.  A  partial 
response  (PR)  was  defined  as  an  estimated  ≥50%  decrease  in 
tumor  size  with  no  detectable  new  lesions.  Progressive  disease 
(PD)  was  defined  as  the  appearance  of  any  new  tumor  lesions 
or  a  ≥25%  increase  in  the  size  of  the  existing  tumor  lesions. 
When  the  responses  did  not  qualify  as  CR,  PR  or  PD,  then 
they  were  reported  as  stable  disease  (SD).  Toxicity  was 
assessed  on  days  1  and  8  of  a  21-day  cycle  for  the  weekly 
regimen  and  on  day  1  of  a  21-day  cycle  for  the  3-week  regimen. 
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Characteristics  Weekly  docetaxel 3‐weekly  docetaxel
No.  of  patients % No.  of  patients %
No.  of  patients  included
Age  (years)
        Median
        Range
Gender
        Male
        Female
Performance 
        1
        2
Stage
        IIIB
        IV
Histological  type  of  cancer
        Adenocarcinoma
        Squamous  carcinoma
        Large  cell  carcinoma
        Other
Previous  treatment
    Combination  therapy
        G
*  +  C
†
        P
‡  +  C
†
        E
§  +  C
†
        V
I|  +  I
¶  +  C
†
    Monotherapy  (G
*)
    CCRT  (P
‡)
No.  of  platinum-based  chemotherapy  sessions  (median)
Response  to  first-line  chemotherapy
        Partial  response
        Stable  disease
        Progressive  disease
Co-morbidity
        Hypertension
        Diabetes  mellitus
        Hepatitis
        PTE**
Site  of  metastasis
        Lung  to  lung
        Brain
        Liver
        Bone
18
64
41-69
10
8
7
11
6
12
10
5
2
1
12
3
1
1
1
4.0
7
6
5
1
2
1
5
1
4
5
55.6
44.4
38.9
61.1
33.3
66.7
55.6
27.8
11.1
5.6.
66.7
16.7
5.6
5.6
5.6
38.9
33.3
27.8
5.6
11.1
5.6
27.8
5.6
22.2
27.8
19
63
33-70
9
10
9
10
2
17
17
2
15
1
1
2
5.0
10
4
5
4
1
2
7
1
5
12
47.4
52.6
47.4
52.6
10.5
89.5
89.5
10.5
78.9
5.3
5.3
10.5
52.7
21.1
26.3
21.1
5.3
10.5
36.8
5.3
26.3
63.2
*gemcitabine, 
†cisplatin, 
‡paclitaxel, 
§etoposide, 
||vinorelbine, 
¶I:  ifosfamide, 
**pulmonary  thromboembolism
Table  1.  Patient  characteristics
Statistics
The  overall  survival  (OS)  duration  was  defined  as  the  time 
between  the  date  of  starting  treatment  and  the  date  of  the  last 
follow-up  or  death.  Time  to  progression  (TTP)  was  defined  as 
the  time  between  the  date  of  starting  treatment  and  the  date  of 
progressive  disease.  The  response  duration  was  calculated  from 
the  day  of  the  observed  response  until  the  day  of  documented 
progression.  The  disease  control  rate  was  defined  as  the 
proportion  of  patients  with  a  partial  or  complete  response  to  an 
investigational  treatment  plus  those  patients  for  whom  their 
disease  had  stabilized.  The  durations  of  the  OS  and  TTP  were 
estimated  using  the  Kaplan-Meier  method  and  the  differences 
between  the  Kaplan-Meier
  curves  were  evaluated  by  the 
log-rank  test. 
RESULTS
Patients'  characteristics
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Weekly  docetaxel  (n=18) 3‐weekly  docetaxel  (n=19)
No.  of
patients
%
months
No.  of
patients
% months
Response
    PR* 
        (95%  CI)
    SD
†
      (95%  CI)
    PD
‡
      (95%  CI)
Unevaluable  patients
∥
3
7
7
1
16.7§
(0-36.0)
38.9§
(14-64)
38.9§
(14-64)
4
8
7
0
21.1
42.1
36.8
Response  duration
    median
    range
2.2
0.7-3.9
2.6
0.2-7.6
Dose  intensity 
    median
    (mg/m
2/wk)
24.0 23.9
*partial  response, 
†stable  disease, 
‡progressive  disease,  §Intention‐to‐treat  analysis, 
∥Unevaluable  patients  are  discussed  in  the  text.
Table  2.  Efficacy
 
Figure  1.  (A)  the  overall  survival  curve  and  (B)  the  time  to  progression  curve
docetaxel  monotherapy  as  a  second-line  treatment  between  Oct 
1,  2003  and  March  31,  2006.  One  patient  on  the  weekly 
schedule  was  excluded  due  to  loss  of  follow-up.  The  patients' 
characteristics  are  summarized  in  Table  1.  Eighteen  patients 
received  weekly  administration  of  docetaxel,  whereas  19 
patients  received  a  3-week  administration  schedule  of 
docetaxel.  The  median  patient  age  was  64  (range:  41～69)  for 
the  weekly  schedule  and  63  (range:  33～70)  for  the  3-week 
schedule.  The  patients'  gender  ratio  was  similar  for  both  the 
weekly  and  3-week  schedules.  The  patients  with  an  ECOG  PS 
of  2  or  those  with  stage  IV  disease  were  examined  more 
frequently  during  the  3-week  schedule.  The  histopathology  most 
frequently  revealed  adenocarcinoma,  which  was  more  common 
for  the  3-week  schedule  (89.5%)  than  for  the  weekly  schedule 
(55.6%).  Thirty-three  patients  (89.2%)  received  platinum-based 
chemotherapy  as  a  first-line  treatment,  and  a  combination  of 
gemcitabine/cisplatin  was  the  most  common  chemotherapy. 
Seven  patients  (38.9%)  from  the  weekly  schedule  and  10 
patients  (52.7%)  from  the  3-week  schedule  responded  to 
first-line  treatment.  Of  the  37  patients  in  this  study,  nine  had 
chronic  diseases,  five  had  hypertension  and  three  had  diabetes 
mellitus.  The  median  time  from  diagnosis  to  initiation  of 
docetaxel  was  7.1  months  (range:  1.9～74.1).  A  total  of  135 
chemotherapy  cycles  were  administered  with  the  median 
A B
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Toxicity
Weekly  docetaxel
(N=63)
3-weekly  docetaxel
(N=72)
Total
(N=135)
G1-2
n  (%)
G3-4
n  (%)
G1-2
n  (%)
G3-4
n  (%)
n  (%)
Hematologic  toxicity
    Leukopenia
    Neutropenia
    Febrile  neutropenia
    Anemia
    Thrombocytopenia
Non-hematologic  toxicity
    Neuropathy
    Asthenia
    Mucositis
    Nausea/Vomiting
    Diarrhea
    ILD
*
16  (25.4)
14  (22.2)
0  (0)
23  (36.5)
3  (4.8)
44  (69.8)
24  (38.1)
17  (27.0)
8  (12.7)
11  (17.5)
2  (3.2)
2  (3.2)
6  (9.5)
2  (3.2)
1  (1.6)
0  (0)
3  (4.8)
0  (0)
0  (0)
0  (0)
0  (0)
1  (1.6)
25  (34.7)
15  (20.8)
0  (0)
40  (55.6)
2  (2.8)
53  (73.6)
23  (31.9)
23  (31.9)
10  (13.9)
5  (6.9)
2  (2.8)
15  (20.9)
28  (38.9)
4  (6.8)
1  (5.5)
0  (0)
1  (1.4)
2  (2.8)
5  (6.9)
3  (4.2)
0  (0)
0  (0)
58  (43.0)
63  (46.7)
6  (4.4)
65  (48.1)
5  (3.7)
101  (74.8)
49  (36.3)
45  (33.3)
21  (15.6)
16  (11.9)
5  (3.7)
*Interstitial  lung  disease
Table  3.  Incidence  of  toxicities
number  of  cycles/patient  being  3.0  (range:  1～9).
Treatment  efficacy
A  response  evaluation  was  assessed  for  a  total  of  37 
patients.  The  objective  response  rate  was  16.7%  (95% 
confidence  interval:  0～36.0)  for  the  weekly  schedule  and  21.1% 
for  the  3-week  schedule.  Disease  control  was  achieved  in  10 
patients  (55.6%)  for  the  weekly  schedule  and  in  12  patients 
(63.2%)  for  the  3-week  schedule.  The  length  of  response  was 
a  median  of  2.2  months  (range:  0.7～3.9)  for  the  weekly 
schedule  and  2.6  months  (range:  0.2～7.6)  for  the  3-week 
schedule  (Table  2).  The  median  overall  TTP  was  2.8  months 
(95%  confidence  interval:  2.3～3.3)  with  a  median  TTP  of  3.0 
months  (95%  confidence  interval:  1.9～4.0)  for  the  weekly 
schedule  and  2.8  months  (95%  confidence  interval,  1.0～4.6)  for 
the  3-week  schedule.  No  significant  differences  were  observed 
between  the  two  different  treatment  schedules  (p=0.41)  (Figure 
1).  The  median  OS  time  was  12.0  months  (95%  confidence 
interval:  5.9～18.1)  for  all  the  patients  with  a  median  OS  of  13.3 
months  (95%  confidence  interval:  6.3～20.3)  for  the  weekly 
schedule  and  a  median  OS  of  10.7  months  (95%  confidence 
interval:  8.3～13.0)  for  the  3-week  schedule.  The  2.6  months 
difference  in  the  OS  between  the  2  groups  was  not  statistically 
significant  (p=0.41)  (Figure  1).  Out  of  the  24  patients  (weekly 
schedule:  3  males  and  6  females,  3-week  schedule:  4  males 
and  7  females)who  had  been  on  a  third-line  therapy  after 
docetaxel  therapy,  20  received  an  EGFR  tyrosine  kinase 
inhibitor  (TKI),  and  the  remaining  four  were  treated  with 
gemcitabine/vinorelbine  combination  chemotherapy.
Toxicity
Toxicity  was  quantifiable  in  all  135  cycles  and  the  treatment- 
linked  severe  toxicities  including  grade  3  or  more  neutropenia 
(25.2%),  which  occurred  much  more  frequently  in  the  3-week 
schedule  (28  cycles,  38.9%)  as  compared  with  the  weekly 
schedule  (6  cycles,  9.5%).  Febrile  neutropenia  was  observed 
during  2  cycles  for  the  weekly  schedule  and  this  was  observed 
during  4  cycles  for  the  3-week  schedule.  Grade  3  or  more 
anemia  occurred  in  only  2  cycles  and  no  severe  thrombo-
cytopenia  was  observed.  The  non-hematologic  toxicities  were 
generally  mild  and  they  primarily  included  peripheral  neuropathy 
(101  cycles,  74.8%),  asthenia  (49  cycles,  36.3%)  and  oral 
mucositis  (45  cycles,  33.3%).  Moreover,  grade  3  or  greater 
peripheral  neuropathy  occurred  during  three  cycles  (4.8%)  of  the 
weekly  schedule  and  during  one  cycle  (1.4%)  of  the  3-week 
schedule.  Interstitial  lung  disease  (ILD)  was  found  in  five  cases, 
and  one  of  these  cases  displayed  grade  3  peripheral 
neuropathy  (Table  3).  ILD  was  diagnosed  by  high-resolution 
computed  tomography  and  also  with  excluding  the  infectious 
causes.  Administration  of  chemotherapy  was  postponed  in  19 
cycles.  However,  there  was  no  justification  to  reduce  the 
chemotherapy  doses.  The  administered  docetaxel  dose  intensity 
(D.I.)  for  the  weekly  schedule  was  96%  of  the  planned  D.I.  (25 
mg/m
2/week)  and  it  was  95.6%  for  the  3-week  schedule. 
Moreover,  there  was  no  treatment-related  mortality;  during  the 
median  follow-up  of  8.7  months  (range:  1.8～3.6)  for  37 
patients,  23  patients  died  of  cancer  progression  and  one  patient 
died  of  a  cerebrovascular  event. 
DISCUSSION
Platinum-based  regimens  have  been  the  mainstay  of  lung 
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strated  their  statistically  significant  survival  benefit  over  the  best 
supportive  care  alone  for  treating  advanced  NSCLC
1).  Those 
advanced  NSCLC  patients  who  exhibit  disease  progression  or 
local  relapse  after  first-line  chemotherapy  may  be  candidates 
for
  second-line  treatment.  Two  drug  combination  regimens  have 
shown  increased  toxicities  without  any  survival  benefits,  and  the 
increased  toxicity  has  sometimes  led  to  toxicity-related  deaths. 
Consequently,  single-agent  chemotherapy  has  been  actively 
attempted,  and  this  has  become  the  preferred  treatment  option 
in  a  second-line  setting
14).  Of  the  newer  cytotoxic  drugs  that  are 
used  for  treating
  NSCLC,  gemcitabine,  vinorelbine,  taxane  and 
pemetrexed  monotherapy  have  been  widely  explored  for  treating 
NSCLC  patients  who  failed  their  front-line  treatment.  Docetaxel 
monotherapy  in  the  previous  phase  II  studies  has  demonstrated 
promising  results  with  a  response  rate  of  16～22%  and  a 
median  survival  of  6.9～9.7  months
5, 6).  The  phase  III  trials  have 
shown  statistically  greater  differences  of  the  median  survival 
time  (5.7～7.5  months),  the  1-yr  survival  rate  (32～37%)  and  the 
quality  of  life  in  comparison  to  the  control  groups  (the  best 
supportive  care,  or  vinorelbine  or  ifosfamide  monotherapy),  and 
this  is  despite  the  low  response  rates  (less  than  10%)
2, 3). 
Vinorelbine
3),  paclitaxel
9)  and  gemcitabine
15)  monotherapy  have 
shown  response  rates  of  20%,  0.8%  and  14%,  respectively,  and 
a  median  survival  duration  of  5.5  months,  5.6  months  and  3.7 
months,  respectively.  However,  these  drugs  have  not  been 
accepted  as  standard  second-line  chemotherapy  for  advanced 
NSCLC  patients  because  of  the  poor  clinical  outcome  compared 
to  docetaxel  monotherapy
3, 9).  A  large-scale  randomized  phase 
III  trial  has  recently  compared  pemetrexed  and  docetaxel  as 
second-line  monotherapy  treatments,  and  the  results  have 
indicated  similar  efficacy  and  significantly  improved  safety
4). 
The  TAX320  study  was  a  3-arm,  phase  III  randomized  trial 
that  compared  docetaxel  (100  mg/m
2  to  start  and  then  75  mg/m
2 
every  3  weeks)  and  a  “standard”  arm  of  either  vinorelbine  or 
ifosfamide
3).  This  trial  established  the  superiority  of  docetaxel,  at 
the  intermediate  dose  of  75  mg/m
2,  for  the  response  rate,  the 
time  to  progression  and  the  overall  survival  of  the  study 
patients.  Shim  et  al.  reported  that  75  mg/m
2  of  docetaxel 
monotherapy  every  3  week  was  also  effective  in  a  Korean 
population  with  a  response  rate  of  18.2%  and  a  median  survival 
time  of  11  months
16).
Despite  these  promising  results,  docetaxel-associated  toxicity 
is  known  to  be  a  significant  factor  during  therapy.  In  the  TAX 
320  trial
3),  the  occurrence  of  grade  3  or  more  neutropenia  was 
more  frequent  (54%)  for  the  docetaxel  75  mg/m
2  group 
compared  to  that  of  the  vinorelbine  or  ifosfamide  group  (31%). 
In  the  effort  to  reduce  the  hematologic  toxicities  of  the  3-week 
administration  schedule,  four  randomized  trials  were  conducted 
with  using  different  dosages  and  schedules  of  the  standard 
treatment.  In  a  phase  II  trial  conducted  by  Geravis  et  al
10), 
similar  efficacy  was  observed  between  a  weekly  schedule  and 
3-week  schedule  of  docetaxel  monotherapy  with  response  rates 
of  3.2%  and  4.8%,  respectively,  a  median  survival  duration  of 
5.8  months  and  5.5  months,  respectively,  a  1-yr  survival  rate  of 
6%  and  18%,  respectively.  Moreover,  several  phase  III  trials 
have  shown  a  response  rate  of  5.5～10.5%  and  2.7～12.6%, 
respectively,  and  a  median  survival  duration  of  6.1～9.2  months 
and  5.8～6.7  months,  respectively,  for  the  weekly  and  3-week 
regimens  of  docetaxel  monotherapy
11-13).  In  our  study,  there 
were  no  significantly  differences  in  efficacy  between  the  weekly 
and  3-week  regimens  with  response  rates  of  16.7%  and  21.1%, 
respectively.  (p=0.57),  median  TTPs  of  3  months  and  2.8 
months,  respectively  (p=0.41)  and  median  OSs  of  13.3  months 
and  9.3  months,  respectively  (p=0.41),  for  the  weekly  and 
3-week  regimens.  Although  the  3-week  regimen  group  included 
more  female  patients  and  more  adenocarcinoma  patients,  the 
proportion  of  female  adenocarcinoma  patients  (54.5%)  who 
received  EGFR  TKI  as  a  third-line  treatment  was  similar  to  that 
of  the  weekly  regimen  group  (44.4%).  In  addition,  several 
pharmacokinetics  (PK)  studies  have  provided  data  that  the  PK 
parameters,  including  the  half  life,  clearance  and  area  under  the 
concentration-time  curve  (AUC)  were  similar  between  the 
weekly  and  3-week  schedule
17, 18).  Baker  et  al.  have  reported 
that  the  plasma  concentration  of  docetaxel  was  maintained  as 
0.5  nM  for  21  days  in  the  3-week  docetaxel  group  and  the 
plasma  concentration  was  measured  in  the  weekly  group
  as  1.0 
nM  for  the  whole  7  day  period  after  its  administration
17).  It  has 
been  suggested  that  the  anti-tumor  efficacy  of  taxanes  come 
about  both  by  inhibiting  the  mobility  of  microtubules  and  the 
anti-angiogenesis  effect  at  a  relatively  lower  intracellular 
concentration
19, 20).  These  data  support  the  clinical  results  of 
weekly  docetaxel  monotherapy. 
In  a  randomized  phase  III  trial
12),  Scheutte  et  al.  reported  that 
a  weekly  docetaxel  regimen  was  unlike  the  3-week  regimen 
with  respect  to  the  toxicity  profile.  The  incidence  of  grade  3  or 
more  neutropenia  and  anemia  were  4.8%  and  1.0%, 
respectively,  in  the  weekly  arm  compared  to  20.6%  and  5.9%, 
respectively,  in  the  3-week  arm.  In  our  study,  the  incidence  of 
grade  3  or  more  neutropenia  in  the  3-week  arm  and  the  weekly 
arm  concurred  with  these  previous  findings  (38.9%  and  9.5%, 
respectively,  in  our  study).  Because  polysorbate  80,  which  is  a 
vehicle  for  docetaxel,  competes  with  docetaxel  itself  for  binding 
plasma  α-1-acid  glycoprotein,  a  higher  dose  of  docetaxel  may 
give  rise  to  an  increased  plasma  concentration  of  the  unbound 
form
21).  Past  studies  have  shown  that  the  pharmacokinetics  of 
the  unbound  forms,  rather  than  that  of  the  total  docetaxel,  are 
more  closely  correlated  with  the  incidence  and  severity  of 
neutropenia  due  to  docetaxel  administration
22).  Although  the 
reason  for  the  different  toxicity  profile  has  not  been  clearly 
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explanations.  In  contrast  to  the  clinical  trials  that  used  docetaxel 
in  a  first-line  setting,  the  most  common  non-hematologic  toxicity 
in  our  study  was  peripheral  neuropathy,  and  this  was  seen  in 
74.8%  of  the  patients.  This  finding  might  be  associated  with  an 
accumulation  of  peripheral  nerve  injury  by  platinum  because 
most  of  the  patients  had  received  platinum-based 
chemotherapy  as  a  first-line  treatment.  Other  toxicity  symptoms 
included  asthenia,  oral  mucositis  and  gastrointestinal  symptoms. 
No  difference  was  observed  for  the  non-hematological  toxicities 
between  the  two  groups,  except  for  peripheral  neuropathy.  In 
addition,  severe  peripheral  neuropathy  over  grade  3  occurred 
more  frequently  in  the  patients  of  the  weekly  regimen  (4.8%)  as 
compared  to  that  of  the  patients  of  the  3-week  regimen  (1.4%). 
In  the  CALGB  9840  study  that  compared  paclitaxel  80  mg/m
2 
weekly  (n=234)  with  175  mg/m
2  every  3  weeks  (n=230)  for 
treating  advanced  breast  cancer  patients,  a  severe  sensory  type 
of  peripheral  neuropathy  (over  grade  3)  occurred  in  19%  of  the 
patients  of  the  weekly  group  and  in  12%  of  the  patients  in  the 
3-weeks  group  (p=0.001)
23).  However,  there  was  no  significant 
difference  of  peripheral  neuropathy  between  the  schedules  in 
the  phase  III  trials  of  NSCLC  that  compared  weekly  docetaxel 
with  3-week  docetaxel
11, 13).  With  regard  to  pulmonary  toxicity, 
ILD  was  found  in  five  cases  (3  weekly  cases  and  2  3-week 
cases).  All  the  cases  developed  ILD  1  month  after  therapy  had 
begun.  In  one  case,  a  lung  biopsy  finding  showed  bronchiolitis 
obliterans/organizing  pneumonia;  infiltration  of  mononuclear  cells 
into  the  alveolar  septa  and  interstitial  fibrosis  was  observed  in  2 
cases.  Even  though  serious  ILD  of  more  than  grade  3  was 
observed  in  one  weekly  regimen  case,  this  patient  recovered 
after  steroid  treatment.  The  co-morbid  diseases  afflicting  the 
study  patients  included  diabetes  mellitus  with  nephropathy, 
COPD  and  decreased  pulmonary  function  after  previous 
lobectomy.  Three  cases  received  gemcitabine/cisplatin,  one 
case  received  etoposide/cisplatin  and  another  case  received 
paclitaxel-based  concurrent  chemoradiotherapy  as  first-line 
chemotherapy.  We  cannot  make  conclusions  about  the 
relationship  between  the  administration  schedule  and  the 
non-hematologic  toxicities  (e.g.,  peripheral  neuropathy,  ILD,  etc.) 
with  such  a  small  sample  size. 
Our  study  is  limited  by  a  small  patient  sample  size,  and  their 
quality  of  life  or  their  satisfaction  with  the  treatment  could  not  be 
evaluated  because  of  the  study's  retrospective  nature.  Despite 
these  limitations,  this  study  affirmed  that  the  weekly  regimen  of 
docetaxel  monotherapy  has  an  equally  favorable  toxicity  profile 
compared  to  the  3-week  schedule.  This  study  supports  that  a 
weekly  schedule  of  docetaxel  monotherapy  is  a  reasonable 
alternative  for  those  NSCLC  patients  who  fail  with  first-line 
platinum-based  chemotherapy. 
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